No Data
No Data
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Cardiol Therapeutics Schedules Virtual Annual General Meeting for May 2025
Cardiol Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Roth MKM Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $10
Roth MKM Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)
Buy Rating for Cardiol Therapeutics Driven by CardiolRx Progress and MAVERIC Phase 3 Trial Initiation